Canada markets closed

Repro Med Systems, Inc. (KRMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.5200+0.1200 (+3.53%)
At close: 4:00PM EDT
Sign in to post a message.
  • R
    Robert
    ⭐ This is a very Bullish Chart, traders! 💰💵📈

    https://stockreport.tips/Bullish-Charts
  • D
    Darrell
    First Quarter 2021 Financial Results
    Net sales were $5.4 million for the three months ending March 31, 2021, a 14% decrease from $6.3 million in the same period of 2020
  • T
    Tom
    Good Q1 2020 results. What’s people’s thoughts?
  • T
    The _Salty_One
    I’m in at $5.76. My research is showing that $9.50 is a fair and achievable price.
  • t
    trailr
    FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies

    Barcelona, July 4, 2019.- Grifols, a leading global producer of plasma-derived medicines, announced today that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify is used to treat primary immunodeficiencies

    RMS has partnered with Grifols to provide the pumps. This is a validation of the RMS strategy of partnering with drug companies as they introduce Sub Q therapies. The revenue stream from this partnership looks to start by the end of the year.

    https://www.drugs.com/newdrugs/fda-approves-xembify-immune-globulin-subcutaneous-primary-immunodeficiencies-5012.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Xembify+%28immune+globulin+subcutaneous%29+for+Primary+Immunodeficiencies
  • t
    trailr
    Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that Dan Goldberger, Executive Chairman, will be presenting at the 29th Annual Oppenheimer Healthcare Conference in New York, NY on Tuesday, March 19th.
  • i
    itssofine2
    OK Repro, I took a long position yesterday.....Make me proud.
  • t
    trailr
    Q1 earnings to be released Tuesday after market closes with CC the following day before market opens. Stock seems to be trending up on good volume prior to earnings. Same thing happened last quarter and investors were disappointed. This quarter will be different. The one time expenses of last quarter are behind us. Some fourth quarter sales were delayed until this quarter. Look for 20% YOY top line growth, Bottom line looks like a return to profitability. First quarter with new management team at the wheel. This is the first, very early peek at how they are doing.I am crossing my fingers and expecting better things down the line.
  • l
    l
    We should all do what GameStop did!!
  • t
    trailr
    RMS Medical Products Receives Another Favorable Court Ruling
    Download as PDFSeptember 03, 2019
    CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical” or “the Company”) today announced that on August 30, 2019 the United States District Court for the Southern District of New York (Case No. 1:18-cv-05880-LGS) issued a decision granting RMS Medical’s motion for summary judgement of non-infringement against EMED Technologies (“EMED”) U.S. Patent 9,808,576 (“576 Patent”) and dismissed the case with prejudice.

    On November 7, 2017, EMED filed this case in the United States District Court for the Eastern District of Texas claiming patent infringement of the ‘576 Patent by the Company’s needle sets and seeking unspecified monetary damages. The case was later transferred to the United States District Court for the Southern District of New York and is one of several pending between RMS Medical and EMED.
  • N
    Nicole
    Analysts rose rates to strong buy
  • e
    edu
    why there isn't anual report yet??
  • m
    mookie
    KRMD to be added to the Russell index as of Friday, the 26th. This means all those ETFs that follow the Russell indices have to include KRMD in their portfolios. Look for increased volume over the next to weeks as buying increases. This usually translates into a 10% increase in share price, just more good news for us longs!!
  • A
    Alex
    27.3M$ in cash
  • t
    trailr
    RMS Medical Products initiated with a Buy at Craig-Hallum Craig-Hallum analyst Alexander Nowak started RMS Medical Products with a Buy rating and $5.50 price target. With a trend toward in-home infusion, an overabundance of drugs moving to subQ and a company now focused on the pump partnership opportunity, the analyst believes RMS could ultimately become a much larger medical device supplier.

    I suspect additional analysts will follow.
  • A
    Anonymous
    Apellis' Soliris rival Empaveli snags FDA approval in PNH
    by Noah Higgins-Dunn | May 14, 2021 5:15pm

    More than a year after Apellis Pharmaceuticals proved its C3 inhibitor pegcetacoplan could go head-to-head with industry heavyweight Soliris in patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH), the biotech is finally getting its shot at the market.

    The FDA on Friday approved Apellis' subcutaneous pegcetacoplan, marketed as Empaveli, for the treatment of adults with PNH. The disease is a rare, chronic blood disorder characterized by the destruction of healthy, oxygen-carrying red blood cells both inside and outside the blood vessels, known as hemolysis.

    The destruction is driven by an uncontrolled immune system and defective bone marrow not making enough blood components. Apellis’ C3 therapy, which targets a different enzyme than Alexion's C5 inhibitors, is designed to regulate that excessive immune response.
  • H
    HJP
    Lost more than 1/2 of my investment in krmd.
    Willing to get out if my loss would be increased by 1/3.
  • R
    Rita
    Why is the stock down again??
  • S
    Stock
    There is no justifiable reason for this stock to be trading so high. At $19MM in total revenue TTM, REPR is trading at 7.5x current revenue and would need to grow to ~$50MM in 2-3 years to support today's price. The company has not been able to expand its global business, has not introduced any relevant new products, and continues to lag behind others in their segment. This is definitely a stock to sell now before the price dips.
  • e
    edu
    where is the bottom ?